Skip to main content

Table 1 AMSTAR2 classification of the included studies

From: Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review

Study

Q1

Q2*

Q3

Q4*

Q5

Q6

Q7*

Q8

Q9*

Q10

Q11*

Q12

Q13*

Q14

Q15*

Q16

AMSTAR-2 overall quality

ALESSANDRO RIZZO, 2020  [22]

Y

N

N

Y

N

Y

N

PY

PY

N

Y

Y

Y

Y

N

Y

Critically low

Lawrence Chen, 2016 [16]

Y

Y

Y

Y

N

Y

N

PY

PY

N

N

N

Y

Y

N

Y

Critically low

Ting Zheng, 2020 [19]

Y

N

N

PY

N

Y

N

PY

PY

N

N

Y

Y

Y

Y

Y

Critically low

Xin ZHUANG, 2017 [21]

Y

N

N

PY

N

Y

Y

PY

PY

N

Y

Y

Y

Y

Y

Y

Low

Heng Liu, 2014 [18]

Y

N

Y

PY

N

Y

Y

PY

PY

N

Y

Y

Y

Y

Y

Y

Low

Sheng Zhao, 2016 [17]

Y

N

N

Y

N

Y

N

PY

PY

N

Y

Y

Y

Y

Y

Y

Critically low

Alessandro Rizzo, 2022  [26]

Y

N

N

Y

Y

Y

N

PY

PY

N

N

Y

Y

Y

N

Y

Critically low

Wen-Jie Ma,2020  [27]

Y

N

Y

Y

Y

Y

N

Y

PY

N

Y

Y

Y

Y

Y

Y

Critically low

Julien Edeline, 2022  [28]

Y

N

Y

N

N

N

N

Y

N

N

N

Y

Y

N

N

Y

Critically low

Abdel-Rahman O, 2018 [29]

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

High

Yan Li, 2019 [30]

Y

N

N

Y

Y

Y

N

Y

N

N

N

N

N

N

Y

Y

Critically low

Jie Ying, 2019  [31]

Y

PY

N

Y

N

Y

N

PY

PY

N

N

Y

N

N

Y

Y

Critically low

Wei Zheng, 2019 [32]

Y

N

N

Y

N

Y

N

PY

N

N

N

N

N

Y

Y

Y

Critically low

Yanfeng Jiang, 2021 [33]

Y

N

Y

PY

N

Y

N

PY

PY

N

N

N

Y

Y

Y

Y

Critically low

  1. AMSTAR-2 items: Q1: Did the research questions and inclusion criteria for the review include the components of PICO? Q2: Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review, and did the report justify any signifificant deviations from the protocol? Q3: Did the review authors explain their selection of the study designs for inclusion in the review? Q4: Did the review authors use a comprehensive Literature search strategy? Q5: Did the review authors perform study selection in duplicate? Q6: Did the review authors perform data extraction in duplicate? Q7: Did the review authors provide a list of excluded studies and justify the exclusions? Q8: Did the review authors describe the included studies in adequate detail? Q9: Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? Q10: Did the review authors report on the sources of funding for the studies included in the review? Q11: If meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results? Q12: If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? Q13: Did the review authors account for RoB in primary studies when interpreting/discussing the results of the review? Q14: Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? Q15: If they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? Q16: Did the review authors report any potential sources of conflflict of interest, including any funding they received for conducting the review?
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us